Company History

November 2011
Ellansé™ has reached a milestone since it's official launch in January 2010; it is now marketed and sold in over 50 countries worldwide.

September 2011
Excellent three month interim clinical study results with Ellansé™ Hands due to its unique elastic, viscous gel and volumizing characteristics. Study ongoing.

July 2011
Sales progress on track. Successful uptake of Ellansé™ in world-wide market. Ellansé™ registered and sold in over 42 countries.

February 2011
AQTIS Medical BV wins the 2011 Frost & Sullivan European Technology Innovation of the Year Award in Dermal Fillers in recognition of its pioneering Ellansé™.
Read the full story here!

December 2010
Successful treatment of patient hands and lipo-atrophy patients due to Ellansé™'s unique elasticity/viscosity gel flowing and volumizing characteristics.

November 2010
Successful closure of the 2-year clinical study, with outstanding safety and efficacy data. Study results provide statistical evidence for the Ellansé™ product family performance, evidencing its unique safety and tunable efficacy characteristics. Data to be published early 2011.

October 2010
Progress Ellansé™ Lidocaine development project on-track. Registration planned for Q3 2011.

August 2010
International Medical Advisory Committee meeting, Amsterdam, The Netherlands.

July 2010
Sales progress on track. Succesful uptake of Ellansé™ in world-wide market. Sales in over 20 countries.

May 2010
18-months Clinical Study (ongoing) data provide statistical evidence for the Ellansé™ product family, further evidencing its unique safety and tunable efficacy characteristics.

March 2010
First International Distributors Meeting at AQTIS Medical, Utrecht/Amsterdam, The Netherlands.

February 2010
15-months Clinical Study (ongoing) data provide statistical evidence for the Ellansé™ product family, proving its unique safety and tuneable efficacy characteristics.

January 2010
Successful launch of the Unique Ellansé™ Dermal Filler Family at the IMCAS 2010, Paris, France.

November 2009
12-months Clinical Study (ongoing) data provide statistical evidence for the Ellansé™ product family, proving its unique safety and tuneable efficacy characteristics.

September 2009
Successful implementation of SAP Business One.

June 2009
Roll-out of the international marketing and sales network.

May 2009
AQTIS Medical™ wins CE certification for the entire Ellanse™ product family (S, M, L, E).

April 2009
Installation and validation of additional manufacturing equipment and production capacity.

November 2008
Start Clinical Study at Clinic Study Site 'hautok', München, Germany.

August 2008
ISO-10993 pre-clinical Studies completed.

July 2008
AQTIS Medical™ wins ISO-13485 Certification.

December 2007
GMP-C / ISO Class 7 Cleanroom and aseptic operations completed.

January 2007
Ellansé™ dermal filler family development initiated.

December 2006
Research & Development setup.
Laboratory and offices setup.

November 2006
AQTIS Medical™ was founded.